1 中国高血压防治指南修订委员会. 中国高血压指南2010[J]. 中华高血压杂志, 2010, 19:701-743.

2 王鸿懿, 孙宁玲, 喜杨, 等. 高血压患者糖代谢状况调查及筛查结果分析[J]. 北京大学学报医学版, 2007, 39:603-606.

3 李建平, 霍勇, 刘平, 等. 马来酸依那普利叶酸片降压、降同型半胱氨酸的疗效和安全性[J]. 北京大学学报医学版, 2007, 39:614-618.

4 Gupta AK, Arshad S, Poulter NR. Compliance, safety,and effectiveness of fixed-dose combinations of antihypertensive agents:a meta-analysis[J]. Hypertension, 2010, 55:399-407.

5 Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]. N Engl J Med, 2010, 362:1575-1585.

6 Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study(INVEST):a randomized controlled trial[J]. JAMA, 2003, 290:2805-2816.

7 Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose:observations from traditional and Bayesian random-effects meta-analyses of randomized trials[J]. Circulation, 2011, 123:2799-2810.

8 Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management[J]. Clin Ther, 2011, 33:1190-1203.